PTC Therapeutics has signed an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG, for its PTC518 Huntington’s disease programme, which includes related molecules.

Novartis will assume responsibility for PTC518’s development, manufacturing and commercialisation, following the completion of the on-going placebo-controlled portion of PIVOT-HD, which is expected to occur in H1 2025. The companies will share US profits and losses, on a 40/60 basis (40% PTC and 60% Novartis). The closing of the transaction is subject to customary closing conditions, including regulatory clearance. The parties anticipate that the agreement will close in the first quarter of 2025.